FAZ-3532 

FAZ-3532 is a G3BP inhibitor (K_d = 0.54 μM) which binds to the NTF2L nsP3 binding pocket in G3BP1. FAZ-3532 disrupts the co-condensation of RNA, G3BP1, and caprin 1. FAZ-3532 inhibits G3BP-driven stress granule formation. FAZ-3532 can be studied as a powerful tool to probe the biology of stress granules and a promising interventions designed to modulate stress granule formation^[1].

FAZ-3532 (Compound G3Ia) (10-50 μM) potently displaces the FGDP peptide from the NTF2L domain and exerts tight binding with NTF2L domain^[1].
FAZ-3532 (10 nM-100 μM) disrupts the co-condensation of molecules in the mixture of 1.5 μM of G3BP1, 1.5 μM caprin 1, and 20 ng/μM RNA, where it effectively disrupts the binding of G3BP1 with caprin 1 and reduces condensation of G3BP1 with RNA^[1].
FAZ-3532 (5-50 μM, 20 min) robustly inhibits stress granule formation in a dose-dependent manner in U2OS cells stably expressing G3BP1-GFP with NaAsO₂ (500 μM)-induced stress granule formulation^[1].
FAZ-3532 (50 μM, 2 min) spontaneously reduces stress granule area by ~74% in U2OS cells stably expressing G3BP1-GFP with sodium arsenite (250 μM)-induced stress granule formulation^[1].
FAZ-3532 (50 μM, 60 min) blocks both spontaneous and arsenite-induced stress granule formation in iPSC-derived cortical neurons exposed simultaneously to NaAsO₂ (500 μM)^[1].
FAZ-3532 (50 μM, 30 min) dissolves 83% of the granules in GFP-VCP A232E transfected U2OS cells ^[1].
FAZ-3532 (50 μM, 30 min) reduces the area of G3BP1 found in puncta of FUS R495X transfected U2OS cells compared with vehicle-treated cells, suggesting the inhibiton of G3BP1 condensation does not prevent the inclusion of mutant FUS protein into cytoplasmic puncta^[1].
FAZ-3532 (50 μM, 30 min) Increases ANXA5-FITC-positive apoptotic cells when combined with Cisplatin (HY-17394)^[2].
FAZ-3532 (50 μM, 72 h) reduces tumorsphere size and increases global cell death^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

713.88

C₃₈H₅₆FN₅O₇

3036029-72-5

Solid

White to off-white

C[C@H]([C@H](NC([C@H](C(C)(C)O)NC([C@H](CC(C)(C)C)F)=O)=O)C(N[C@H](C)C(N[C@@H](CCOC)C(N(C)CC1=CC=CC=C1)=O)=O)=O)C2=CC=CC=C2

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Brian D Freibaum, et al. Identification of small molecule inhibitors of G3BP-driven stress granule formation. J Cell Biol. 2024 Mar 4;223(3):e202308083.  [Content Brief]

  [2]. Kim, H. J., et al., (2025). TBK1 is a signaling hub in coordinating stress-adaptive mechanisms in head and neck cancer progression. Autophagy, 1–23. Advance online publication.  [Content Brief]